immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron’s technology platform is capable of developing an

Immuron Limited American Depositary Shares

Sold all IMRN

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Devin White

New position in IMRN

Arjun Banerjee

Kyle

Sold 50% of IMRN

Bought 100% more IMRN

Saket Mehta

Sold 80% of IMRN

Jared Erondu

Bought 150% more IMRN

Bought 33% more IMRN

Bought 200% more IMRN